

Dopa-responsive Dystonia with a Novel Initiation Codon Mutation in the *GCH1* Gene Misdiagnosed as Cerebral Palsy

Jae-Hyeok Lee¹, Chang-Seok Ki²,
Dae-Seong Kim¹, Jae-Wook Cho¹,
Kyung-Phil Park¹ and Seonhye Kim¹

¹Department of Neurology, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan; ²Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Received: 23 March 2011

Accepted: 19 July 2011

Address for Correspondence:
Chang-Seok Ki, MD

Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea
Tel: +82.2-3410-2709, Fax: +82.2-3410-2719
E-mail: changski@skku.edu

Dopa-responsive dystonia (DRD) is a clinical syndrome characterized by childhood-onset dystonia and a dramatic response to relatively low doses of levodopa. However, patients with DRD can be misdiagnosed as cerebral palsy or spastic diplegia due to phenotypic variation. Here we report a young woman with DRD who were severely disabled and misdiagnosed as cerebral palsy for over 10 yr. A small dose of levodopa restored wheelchair-bound state to normality. However, thoracolumbar scoliosis has remained as a sequel due to late detection of DRD. Genetic analysis by using PCR-direct sequencing revealed a novel initiation codon mutation (c.1A>T; p.Met1Leu) in GTP cyclohydrolase 1 (*GCH1*) gene. Although it is known that DRD can be misdiagnosed as cerebral palsy, this case reinforces the importance of differential diagnosis of DRD from cerebral palsy.

Key Words: Dystonia, Dopa-responsive; *GCH1* Gene; Mutation; Cerebral Palsy; Diagnostic Errors

INTRODUCTION

Dopa-responsive dystonia (DRD) is a progressive primary dystonia that is characterized by onset during childhood, circadian fluctuation of symptoms and a dramatic and sustained response to low doses of oral administration of levodopa (1). DRD is frequently caused by GTP-cyclohydrolase 1 (GTPCH1) deficiency that up to 87% of the DRD is caused by mutations in the *GCH1* gene encoding GTPCH1 (2, 3).

Although it is well-known that the clinical features of GTPCH1-deficiency can be extremely variable including benign adult-onset parkinsonism, various types of focal dystonia, DRD simulating cerebral palsy or spastic paraplegia, clinical diagnosis is still a challenge in some instances (4).

In Korea, there has been a few reports on the patients with DRD carrying the *GCH1* mutations (5-10). Here, we report a young woman with a novel initiation codon mutation in the *GCH1* gene who was severely disabled and misdiagnosed as cerebral palsy over than 10 yr.

CASE DESCRIPTION

She was referred to our clinic when she was 30 on February 22,

2009. She developed well until the age of 8 yr when an abnormal tiptoe gait was observed. It resulted in frequent falls. Her symptoms were mild in the morning and more prominent toward the end of the day. As the disease progressed, she had pes equinovarus posture at rest in both feet. At the age 15 she needed the support of two people to walk a short distance and started to use a wheelchair. At this age she also experienced stiffness and twisting in upper limbs, neck, and trunk. She found it difficult to write and use a chopstick. Her birth and developmental history was unremarkable. She had no prior history of head injury, meningitis, encephalitis, or febrile seizures. There was no known history of motor disorder in her family. She was initially diagnosed as having cerebral palsy. Brain CT was normal. She received physiotherapy and muscle relaxants with no benefit. When she was 20, Madopar[®] 250 mg was prescribed by neurologist. Her symptoms dramatically improved within days, and she could walk independently. She had been taking levodopa 200 mg/day for 10 yr with sustained benefit without emergence of motor fluctuations or other neurologic manifestations. She felt well and was leading a normal life. The fixed scoliotic deformity of thoracolumbar spine was noted on chest radiography (Fig. 1). Genetic testing using direct sequencing revealed a novel initiation codon mutation (c.1A>T; p.Met1Leu) in the *GCH1* gene (Fig. 2).

DISCUSSION

DRD-causing mutations in *GCH1* include point mutations, small insertions, deletions and whole exon deletions (2, 11). We identified a novel mutation in the initiation codon. We speculate that the *GCH1* dysfunction caused by c.1A>T is similar to that caused by the previously reported mutations, c.2T>C (p.M1T) and c.3G>C (p.M1I) (12, 13). The initiation codon mutation abolishes the first start codon AUG, which might interfere the translation of *GCH1* gene and cause a decrease in GTPCH1 (enzyme) activity. All three cases with initiation codon mutation presented typical clinical features of DRD, characterized by childhood-onset, started in the legs, and had foot dystonia with equinovarus posture. However, it is difficult to establish a genotype-phenotype corre-

lation because of the limited data.

The classic phenotypic form of DRD presents with childhood-onset foot dystonia, which gradually progresses to other parts of the body, and shows marked diurnal fluctuations with worsening of the symptoms toward the evening and improvement after sleep (1). Many patients have features of parkinsonism, including rigidity, bradykinesia, flexed posture, and loss of postural reflexes. Intellectual, cerebellar, sensory, or autonomic disturbances usually do not occur. However, atypical clinical features may include focal dystonia, spasticity, no dystonia prior to the onset of parkinsonism in mid- or late adulthood, and absence of diurnal fluctuation, making diagnosis difficult (11). Our patient was initially misdiagnosed as having cerebral palsy. In previous series, up to 24% of patients with DRD had been misdiagnosed as cerebral palsy (14). Hyperreflexia, ankle clonus, and other clinical features suggesting spasticity may cause confusion with cerebral palsy. Due to lack of medical records, we were not aware of detailed neurologic findings at pre-treatment state. However, the clinical clues to suggest DRD, such as no developmental abnormalities in early childhood, progressive course, and diurnal fluctuation of symptoms, had been overlooked by her clinicians.

The hallmark of DRD in most cases is a dramatic and persistent response to levodopa (14). Long-term treatment with low dose levodopa is not associated with the motor fluctuations that are seen with levodopa therapy in juvenile (and adult) Parkinson's disease. A small dose restored a wheelchair bound disabled our patient to normality. However, thoracolumbar scoliosis has remained as a sequela due to late detection of DRD. The prognosis of secondary orthopedic deformities has directly related to the timing of diagnosis and the initiation of levodopa therapy (15). Some patients have shown remarkable responsiveness to levodopa with spontaneous resolution of the abnormal spinal curvatures. Therefore, a diagnostic levodopa trial is warranted as soon as possible in patients with early onset dystonia or atypical cerebral palsy of unknown etiology.




Fig. 1. Chest X-ray show fixed scoliotic deformity. The major scoliosis is concentrated in the thoracic region and curves to the right.




Fig. 2. Sequence analysis of the *GCH1* gene identified a heterozygous mutation of the first nucleotide (arrow) in the ATG translation initiation site (c.1A>T; p.Met1Leu).

REFERENCES

1. Segawa M, Hosaka A, Miyagawa F, Nomura Y, Imai H. *Hereditary progressive dystonia with marked diurnal fluctuation*. *Adv Neurol* 1976; 14: 215-33.
2. Hagenah J, Saunders-Pullman R, Hedrich K, Kabakci K, Habermann K, Wieggers K, Mohrmann K, Lohnau T, Raymond D, Vieregge P, Nygaard T, Ozelius LJ, Bressman SB, Klein C. *High mutation rate in dopa-responsive dystonia: detection with comprehensive GCHI screening*. *Neurology* 2005; 64: 908-11.
3. Ichinose H, Ohye T, Takahashi E, Seki N, Hori T, Segawa M, Nomura Y, Endo K, Tanaka H, Tsuji S, Fujita K, Nagatsu T. *Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene*. *Nat Genet* 1994; 8: 236-42.
4. Furukawa Y. *GTP cyclohydrolase 1-deficient dopa-responsive dystonia*. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. *GeneReviews*. Seattle: University of Washington, Seattle, 1993.
5. Hong KM, Kim YS, Paik MK. *A novel nonsense mutation of the GTP cyclohydrolase I gene in a family with dopa-responsive dystonia*. *Hum Hered* 2001; 52: 59-60.
6. Kang JH, Kang SY, Kang HK, Koh YS, Im JH, Lee MC. *A novel missense mutation of the GTP cyclohydrolase I gene in a Korean family with hereditary progressive dystonia/dopa-responsive dystonia*. *Brain Dev* 2004; 26: 287-91.
7. Kim YS, Choi YB, Lee JH, Yang SH, Cho JH, Shin CH, Lee SD, Paik MK, Hong KM. *Predisposition of genetic disease by modestly decreased expression of GCH1 mutant allele*. *Exp Mol Med* 2008; 40: 271-5.
8. Yum MS, Ko TS, Yoo HW, Chung SJ. *Autosomal-dominant guanosine triphosphate cyclohydrolase I deficiency with novel mutations*. *Pediatr Neurol* 2008; 38: 367-9.
9. Jeon BS. *Dopa-responsive dystonia: a syndrome of selective nigrostriatal dopaminergic deficiency*. *J Korean Med Sci* 1997; 12: 269-79.
10. Jeon BS, Jeong JM, Park SS, Kim JM, Chang YS, Song HC, Kim KM, Yoon KY, Lee MC, Lee SB. *Dopamine transporter density measured by [123I] beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia*. *Ann Neurol* 1998; 43: 792-800.
11. Segawa M, Nomura Y, Nishiyama N. *Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease)*. *Ann Neurol* 2003; 54(Suppl 6): S32-45.
12. Tamaru Y, Hirano M, Ito H, Kawamura J, Matsumoto S, Imai T, Ueno S. *Clinical similarities of hereditary progressive/dopa responsive dystonia caused by different types of mutations in the GTP cyclohydrolase I gene*. *J Neurol Neurosurg Psychiatry* 1998; 64: 469-73.
13. Cao L, Zheng L, Tang WG, Xiao Q, Zhang T, Tang HD, He SB, Wang XJ, Ding JQ, Chen SD. *Four novel mutations in the GCH1 gene of Chinese patients with dopa-responsive dystonia*. *Mov Disord* 2010; 25: 755-60.
14. Nygaard TG, Marsden CD, Fahn S. *Dopa-responsive dystonia: long-term treatment response and prognosis*. *Neurology* 1991; 41: 174-81.
15. Tsirikos AI, Carr LJ, Noordeen HH. *Variability of clinical expression and evolution of spinal deformity in a family with late detection of dopa-responsive dystonia*. *Dev Med Child Neurol* 2004; 46: 128-37.